Survivors of childhood ALL exhibit increased rates of neurocognitive deficits. This study was conducted to test whether interpatient variability in neurocognitive outcomes can be explained by polymorphisms in candidate genes conferring susceptibility to neurocognitive decline.
Oxidative Damage May Lead to Neurocognitive Decline
the Cancer Therapy Advisor take:
Oxidative damage may contribute to chemotherapy-associated neurocognitive decline in survivors of childhood acute lymphoblastic leukemia (ALL), according to a recent study published online ahead of print in the Journal of Clinical Oncology.
Researchers led by Peter Cole, MD, of the Albert Einstein College of Medicine examined genomic DNA that was isolated from bone marrow in 350 pediatric leukemia survivors.
“This study was conducted to test whether interpatient variability in neurocognitive outcomes can be explained by polymorphisms in candidate genes conferring susceptibility to neurocognitive decline,” they stated.
These polymorphisms were selected based on prior literature. Multivariable logistic regression models were used to estimate the association between genotype and neurocognitive outcomes.
They found that inferior cognitive or behavioral outcomes were associated with polymorphisms in three genes (NOS3, SLCO2A1, and COMT) that were related to oxidative stress or neuroinflammation.
